Platelet Rich Plasma Versus Corticosteroids in Hip Osteoarthritis Pain

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
LifeBridge Health
Study ID
NCT06793982
Phase
PHASE4
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
21 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Platelet Rich Plasma Joint Injection — DEVICE
    Magellan Autologous Concentration System, ISTO Biologics
  • Corticosteroid Injection — DRUG
    5 milliliters (mL) injection of corticosteroid (1cc Kenalog, 4cc Xylocaine) Kenalog - 40 (triamcinolone acetonide injectable suspension, USP) Xylocaine - MPF (lidocaine HCl Injection, USP)

Study Details

Prospective, single-center that may go on to being multicenter, randomized trial comparing platelet rich plasma (PRP) versus corticosteroid injection for the treatment of symptoms of Hip osteoarthritis. The purpose of the study is to determine which therapy provides a greater reduction in patient reported outcome measures of pain and function.

Key Dates

Start date
Feb 21, 2024
Status verified
Mar 2025
Primary completion
Dec 1, 2025
Completion
Dec 1, 2025

Study Design

Enrollment
54 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Autologous Platelet Rich Plasma
    \~Injection of approximately 10 mL autologous PRP Magellan Autologous Concentration System, ISTO Biologics
  • Active Comparator: Corticosteroid
    5 milliliters (mL) injection of corticosteroid (1cc Kenalog, 4cc Xylocaine) Kenalog - 40 (triamcinolone acetonide injectable suspension, USP) Xylocaine - MPF (lidocaine HCl Injection, USP)

Primary Outcome Measure

Pain Score VAS [ Time Frame: baseline, six weeks, and three months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Sinai Hospital of BaltimoreBaltimoreMaryland21215
Martin Gesheff, DHSc
410-601-9467
Michael A Mont, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Baltimore, MD

Related Studies